XNASAPGE
Market cap2.77bUSD
Dec 24, Last price
47.32USD
1D
-0.38%
1Q
-18.00%
IPO
127.50%
Name
Apogee Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-84m
L+111.10%
CFO
-75m
L+355.11%
Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2023‑12 | 2022‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | 93,003 | 30,727 |
Unusual Expense (Income) | ||
NOPBT | (93,003) | (30,727) |
NOPBT Margin | ||
Operating Taxes | (34) | |
Tax Rate | ||
NOPAT | (93,003) | (30,693) |
Net income | (83,985) 111.10% | (39,785) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 315,391 | 168,317 |
BB yield | -0.05% | |
| Debt | ||
Debt current | 2,202 | |
Long-term debt | 2,967 | |
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | (390,290) | (151,890) |
| Cash flow | ||
Cash from operating activities | (74,761) | (16,427) |
CAPEX | (167) | |
Cash from investing activities | (273,910) | |
Cash from financing activities | 315,391 | 184 |
FCF | (95,597) | |
| Balance | ||
Cash | 395,459 | 151,890 |
Long term investments | ||
Excess cash | 395,459 | 151,890 |
Stockholders' equity | (123,441) | (79,570) |
Invested Capital | 506,489 | 79,570 |
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | 25,005,774 | 50,674 |
Price | 27.94 | |
Market cap | 698,661,326 | |
EV | 698,271,036 | |
EBITDA | (93,003) | (30,727) |
EV/EBITDA | ||
Interest | 9,150 | |
Interest/NOPBT | ||